Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clinical trials of cefoperazone (cefobid, Pfizer, USA) were carried out in 49 patients with cardiovascular diseases who had undergone surgical operations. The pathogens of infectious complications were investigated bacteriologically. Good results of the treatment were observed in 43 patients. Allergic reaction developed in 1 patient. Cefoperazone was shown advantageous in treatment of pulmonary complications in the operated patients. It was found possible to use cefoperazone in combination with aminoglycosides. Cefoperazone was found to be one of the drugs of choice in the treatment of aerobic and anaerobic bacteriemia, as well as sepsis after surgical operations on the heart and great vessels. The results on the use of cefoperazone for short-term "perioperative" prophylaxis in cardiosurgery (in accordance with the WHO instructions) are also presented.
 ...
PMID:[Prevention and treatment with cefoperazone of postoperative suppurative complications in heart surgery]. 145 31

The biliary excretion of cefoperazone and ceftazidime was studied by endoscopic cannulation of the common bile duct, in patients with complete biliary obstruction and in an unobstructed control group. Patients were given each drug prophylactically for 24 h before endoscopy and as a single dose at the time of cannulation. In unobstructed patients biliary excretion of ceftazidime was passive. At the time of cannulation bile contained 10% of the peak serum concentration, rising to 20% 90 min later. Cefoperazone excretion was active. At cannulation biliary concentrations were 200% of the serum peak, 900% at 60 min and 700% at 90 min. In obstructed patients, bile sampled immediately at decompression contained neither antibiotic. Passive excretion of both drugs occurred rapidly after relief of obstruction and biliary concentrations were 20% of maximum serum levels at 60 min. Twenty-four hours later passive excretion had further improved, but the active excretion mechanism of cefoperazone had still not recovered. We conclude that obstruction impairs active as well as passive biliary excretion of antibiotics, that drainage is essential for the control of sepsis in obstructed cholangitis, and that both cefoperazone and ceftazidime achieve similar and therapeutic concentrations in bile during the 24 h after decompression.
 ...
PMID:The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. 218 12

We have recently experienced a case of Vibrio vulnificus septicemia which occurred in a patient with hepatic cirrhosis, and as we were able to give early antibiotic treatment, the patient survived. We would like to report this case here together with another case experienced 2 years ago. Case 1 was a 58-year-old male who was attending our hospital as an outpatient for hepatic cirrhosis. At 5:30 pm on August 8, 1987, he consumed abalone and giant clam and at 9 pm complained of high fever with shaking chills. He was admitted to our department as an emergency case. Cefoperazone was administered resulting in a decline of fever on the following day. During the course of treatment he fell transiently into pre-DIC, but due mainly to the administration of antibiotics his condition was subsided. Case 2 was a 53-year-old male who was under medical care in our hospital for grave hepatic cirrhosis. On October 11, 1985, he consumed sushi and two days later suffered chills and pyrexia. A blood culture revealed Vibrio vulnificus. His condition improved transiently with administration of Cefazolin, but oliguria, hypotension and ascites occurred subsequently, and finally the patient died on the 22nd day.
 ...
PMID:[Two case reports of septic shock due to Vibrio vulnificus with liver cirrhosis]. 250 32

In a prospective, randomized, multicenter study, the efficacy and safety of cefoperazone and the combination ampicillin-tobramycin as initial therapy for patients with severe acute biliary tract infections were compared. Of 77 patients initially entered in the study, definite severe biliary tract infection was confirmed in 67. Sixty-four patients completed treatment. At the end of treatment, 35 of 36 (97%) patients given cefoperazone and 23 of 28 (82%) given ampicillin-tobramycin were cured of their infection (P = 0.07). Pathogens were recovered from the bile in 32 patients; microbiological cures were observed in 18 of 19 (94%) patients receiving cefoperazone and 8 of 13 (62%) receiving ampicillin-tobramycin (P = 0.03). Thirteen patients had septicemia. None (0%) of the eight septicemic patients from the cefoperazone group, but two of five (40%) from the ampicillin-tobramycin group, were clinical failures. Of the isolated pathogens, 51% were resistant to ampicillin, while the resistance rate was 4% for tobramycin and 1% for cefoperazone (P less than 0.001). Biliary concentrations of cefoperazone were maintained at high levels--236 +/- 87 micrograms/ml up to 12 h after administration. Even in the presence of severe obstruction, cefoperazone levels in the bile and gallbladder wall were above MICs for most pathogens. Cefoperazone may be considered as an excellent alternative in the therapy of severe biliary tract infections.
 ...
PMID:Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections. 305 55

Cefoperazone was evaluated as the therapeutic agent in 64 adults with serious infections. Included were pneumonias, urinary tract infections, septicemia, osteomyelitis, joint infections, and superficial infections. A total of 84 organisms, including many multiantibiotic-resistant strains, were designated as the etiological agents. In most patients therapy was initiated before information on cefoperazone sensitivity of the infecting organism was available. This proved suitable in most instances. Clinical response to therapy was excellent in these individuals. Bacteriological responses coincided with the problems of the patient but did not reflect inadequacy of the antibacterial effect of cefoperazone. Adverse effects on renal function, including already impaired function, were not observed.
 ...
PMID:Cefoperazone therapy of serious infections. 621 20

Cefoperazone (CPZ), 50 approximately 200 mg/kg/day, divided into 3 to 4 times/day was drip-infused for 3-20 days to 52 patients (41 patients with acute respiratory tract infection, 6 with urinary tract infection, and 5 with sepsis and/or meningitis. The overall efficacy rate was 92.3%. No adverse reaction was noted. These results indicate the usefulness of CPZ in the treatment of bacterial infections in children.
 ...
PMID:[Clinical studies on cefoperazone in children]. 622 34

A study of the pharmacokinetics of cefoperazone (CPZ), used as the sole antibiotic, was performed in 17 children and neonates. The types of infections treated were 7 UTI, 2 otitis media, 2 RTI, 4 septicemia or severe neonatal infections. Causative bacteria included 6 E. coli, 3 Pseudomonas aeruginosa, 1 C perfringens, 1 Klebsiella pneumoniae and 2 Staphylococcus aureus. Cefoperazone was administered by means of rapid IV injections (over 5 min) or IV infusions BID. The blood samples were taken by means of capillary microtubes at time 0, 0.25, 0.50, 0.75, 1, 2, 4, 6, 8 and 12 hours after the end of the first injection. After centrifugation and freezing at -80 degrees DEG method using modified Difco M2 Agar (Nall plus sodium citrate) and stock organinism Bacillus subtilis Atcc 6633. The results achieved in children and neonates were compared, in the 11 children (mean age 6.5 years). The mean single dose was 53 mg/kg. The mean maxima concentration was 145 mcg/ml and was obtained at 0.5 h. Mean serum half-life is 2.4 h. For the neonates mean age was 16 days and the dosage was 47 mg/kg, the maxima concentration was 232 micrograms/ml and was obtained at 0.6 h. The mean serum half-life was 3.4 h in the 2 groups, serum levels at 12 h were still high with a mean of 6.2 micrograms/ml for the 17 children. It appears that doses of 25-50 mg/kg given BID would be satisfactory.
 ...
PMID:[A study of pharmacokinetics of cefoperazone in children]. 635 26

Cefoperazone (CPZ) was given intravenously to 23 children with the following acute bacterial infections; 10 cases of pneumonia, 4 cases of urinary tract infection, 2 cases of purulent cervical lymphadenitis, 2 cases of pertussis pneumonia, 2 cases of septicemia, 1 case of osteomyelitis, 1 case of perforative peritonitis and 1 case of bacterial meningitis. Clinical effectiveness was obtained in 20 cases out of 23 cases and bacteriological effectiveness in 14 cases out of 17 cases. With CPZ, the following side effects developed; transient diarrhea in 1 case, asymptomatic eosinophilia in 2 cases. From the above clinical results, it is apparent that CPZ is a useful antibiotic for treating pediatric patients with various kinds of bacterial infections.
 ...
PMID:[Clinical experience with cefoperazone in the pediatric field (author's transl)]. 645 40

We report the use of cefoperazone in 62 cases of serious infection, most of which occurred in patients with renal impairment. 43 severe or complicated urinary tract infections, 11 cases of pneumonia and 8 with other severe sepsis were treated with cefoperazone 1 to 2 g twice daily usually for 5 to 10 days. Of the patients with urinary tract infection, all who were symptomatic showed a rapid clinical response; 26 (61%) were cured including 11 of 16 with chronic renal failure; 12 relapsed and 5 were reinfected with a different pathogen. All of these patients were infected by organisms sensitive to cefoperazone by disc testing but in 5 of those who relapsed the cefoperazone MIC was in fact greater than or equal to 50 microgram/ml. Ten of 11 cases with radiologically confirmed pneumonia were cured with cefoperazone. 7 episodes of pneumonia were in patients with end-stage chronic renal failure (6 were on dialysis) and 1 was in a patient with acute renal failure. Seven of 8 cases with severe sepsis were cured with cefoperazone. 1 patient was withdrawn from the study when acute bronchospasm followed a 2 g intravenous dose. 2 of the successfully treated patients had functioning renal transplants, 2 of 3 with severe chronic renal failure were on dialysis and 1 had acute renal failure. Side effects included minor disturbances of liver function in 6 patients (11%), diarrhoea in 7 (13%) and marked alcohol intolerance in one, 4 patients with chronic renal failure developed a coagulation disorder which was corrected with vitamin K. None of the patients showed deterioration in renal function while receiving cefoperazone. Cefoperazone promises to be an effective drug for the treatment of a wide spectrum of severe infections in hospitalised patients including those with impaired renal function.
 ...
PMID:Cefoperazone in the treatment of severe or complicated infections. 645 95

Cefoperazone was given to 33 surgical patients who had bacterial infections. A dose of 1 to 2 g bid was administered intravenously for an average of 8.2 days. The overall satisfactory response rate (which includes excellent and good responses) was 79%: 83% in 18 cases of peritonitis and/or intra-abdominal abscesses. 75% in 8 cases of hepatobiliary infections: 100% in 5 cases of skin and soft tissue infections; and 0 in 2 cases of sepsis. The satisfactory response rates according to the isolated organisms were: 11 of 15 Escherichia coli, 15 of 18 streptococci (including 4 of 6 enterococci) 3 of 6 Pseudomonas aeruginosa. 3 of 4 staphylococci 2 of 3 Proteus species, and 3 of 3 Klebsiella pneumoniae. No side effects were observed and there were no abnormal laboratory findings.
 ...
PMID:Clinical studies with cefoperazone in the treatment of bacterial infections in surgical practice. 645 96


1 2 Next >>